What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Enzyme
- Gene
Yuichi Sugiyama mainly focuses on Pharmacology, Biochemistry, Pharmacokinetics, Transporter and Organic anion transporter 1.
His Pharmacology study combines topics from a wide range of disciplines, such as Efflux, In vitro, In vivo and Pravastatin.
His Biochemistry study frequently links to related topics such as Molecular biology.
His Pharmacokinetics research is multidisciplinary, relying on both Oral administration, Plasma protein binding, Drug metabolism, Hepatocyte and Distribution.
The various areas that Yuichi Sugiyama examines in his Transporter study include Metabolite, Cyclosporin a and Intracellular.
In his study, which falls under the umbrella issue of Organic anion transporter 1, Cimetidine is strongly linked to Kidney metabolism.
His most cited work include:
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (760 citations)
- Novel Cisplatin-Incorporated Polymeric Micelles Can Eradicate Solid Tumors in Mice (502 citations)
- Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions (481 citations)
What are the main themes of his work throughout his whole career to date?
Yuichi Sugiyama mainly investigates Pharmacology, Biochemistry, Pharmacokinetics, Internal medicine and Endocrinology.
Yuichi Sugiyama has researched Pharmacology in several fields, including P-glycoprotein, Efflux, Transporter and In vivo.
His research in In vivo intersects with topics in Microsome, In vitro and Metabolism.
Biochemistry is frequently linked to Molecular biology in his study.
His Pharmacokinetics research incorporates themes from Metabolite, Distribution, Drug metabolism and Oral administration.
He interconnects Abcg2 and Multidrug resistance-associated protein 2 in the investigation of issues within Internal medicine.
He most often published in these fields:
- Pharmacology (41.45%)
- Biochemistry (28.27%)
- Pharmacokinetics (27.93%)
What were the highlights of his more recent work (between 2012-2021)?
- Pharmacology (41.45%)
- Pharmacokinetics (27.93%)
- Transporter (17.09%)
In recent papers he was focusing on the following fields of study:
His main research concerns Pharmacology, Pharmacokinetics, Transporter, Drug and In vivo.
His research in Pharmacology intersects with topics in In vitro, Endogeny, Biochemistry, Organic anion transporter 1 and Organic anion-transporting polypeptide.
Yuichi Sugiyama combines subjects such as MicroDose, CYP3A4, Cytochrome P450 and Oral administration with his study of Pharmacokinetics.
His work in Transporter addresses subjects such as Intestinal absorption, which are connected to disciplines such as P-glycoprotein.
His study in In vivo is interdisciplinary in nature, drawing from both Metformin and Albumin.
He has researched Abcg2 in several fields, including Endocrinology and Internal medicine.
Between 2012 and 2021, his most popular works were:
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (760 citations)
- Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. (261 citations)
- Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver (169 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Internal medicine
- Gene
Pharmacology, Pharmacokinetics, In vivo, Drug and Organic anion transporter 1 are his primary areas of study.
His Pharmacology research integrates issues from Metformin, Organic anion-transporting polypeptide, Transporter, Rifampicin and Endogeny.
His Organic anion-transporting polypeptide study improves the overall literature in Biochemistry.
His biological study spans a wide range of topics, including Metabolite, Fexofenadine, Repaglinide and Distribution.
His In vivo research is multidisciplinary, incorporating elements of Pitavastatin, In vitro and Stem cell.
The concepts of his Organic anion transporter 1 study are interwoven with issues in Cell culture, Probenecid, Benzylpenicillin, Pravastatin and HMG-CoA reductase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
